$CBLL

Ceribell, Inc.

No enriched coverage for $CBLL in the last 7 days.

$3.3M
Blumberg Scott
62%
See all $CBLL insider activity →
Low

Chao Xingjuan sold $973K of CBLL

Chao Xingjuan (President and CEO) sold 39,540 shares of Ceribell, Inc. (CBLL) at $24.61 ($0.97M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Chao Xingjuan sold $146K of CBLL

Chao Xingjuan (President and CEO) sold 6,068 shares of Ceribell, Inc. (CBLL) at $24.02 ($0.15M total) on 2026-08-21.

Blumberg Scott sold $864K of CBLL

Blumberg Scott (Chief Financial Officer) sold 34,502 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.86M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.

CBLL sentiment & insider activity

Recent CBLL coverage spans insider activity, regulation and financial news.

In the last 30 days, CBLL insiders filed 13 SEC Form 4 transactions — no purchases and 13 sales ($3.3M). The most active reporter was Blumberg Scott, Chief Financial Officer, with 4 filings. 62% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving CBLL

alphai scores every news story that mentions CBLL with an AI model for sentiment and relevance, and aggregates insider trades from Ceribell, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CBLL

Score
$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

Related tickers